GlassScriptPhysician profile
Erik S Marshall
NPI 1144223850
$4,226.80
in general payments reported to CMS, 2019-2025
26 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,004 · 2020: $344 · 2021: $107 · 2022: $239 · 2023: $1,308 · 2024: $763 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,236 · Travel and Lodging: $298.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,235.79 |
| Travel and Lodging | $297.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $918.71 | 2023 | Mitraclip |
| Janssen Pharmaceuticals, INC | $465.65 | 2019-2024 | Xarelto |
| Amgen INC. | $461.62 | 2019-2025 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $412.79 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $372.78 | 2019-2025 | Camzyos, Eliquis |
| Novartis Pharmaceuticals Corporation | $287.05 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $229.41 | 2019-2024 | Brilinta, Farxiga, Wainua |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $186.28 | 2019-2025 | Lifevest |
| Lexicon Pharmaceuticals, INC. | $146.17 | 2024 | Inpefa |
| Pfizer INC. | $140.39 | 2019-2025 | |
| Astellas Pharma US INC | $111.17 | 2019-2020 | |
| Medtronic, INC. | $84.55 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.07 | 2025 | |
| Amarin Pharma, INC. | $54.87 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $52.88 | 2024 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $40.08 | 2023 | Nexletol |
| Alnylam Pharmaceuticals INC. | $34.00 | 2019-2025 | |
| Scpharmaceuticals INC. | $29.68 | 2025 | |
| Lantheus Medical Imaging, INC. | $23.92 | 2023 | Definity |
| Heartflow, INC. | $20.00 | 2025 | |
| Janssen Scientific Affairs, LLC | $19.58 | 2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $18.68 | 2019 | |
| Altathera Pharmaceuticals LLC | $16.39 | 2025 | Sotalol Hydrochloride |
| Lilly USA, LLC | $14.84 | 2024 | Mounjaro |
| Bridgebio Pharma, INC. | $14.09 | 2025 | Attruby |
| Regeneron Healthcare Solutions, INC. | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erik Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.